Retinal Disease

A new open access program from Blueprint Genetics, InformedDNA and the Foundation Fighting Blindness will allow patients with inherited retinal disease to receive no-cost genetic testing and genetic counseling in the United States, according to a press release.

The FDA has granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy, Aldeyra Therapeutics announced in a press release.

OCU400, a gene therapy candidate, has received a second orphan drug designation from the FDA for the treatment of CEP290 mutation associated retinal disease, Ocugen announced in a press release.

The FDA has granted 510(k) clearance to Canon U.S.A.’s Xephilio OCT-A1 OCT device, according to a press release.

ONL Therapeutics will begin a first-in-human study of its Fas inhibitor for retinal diseases following the completion of $3 million in convertible note financing, according to a press release.

Iconic Therapeutics has signed an agreement with Novartis that will give Novartis an option on Iconic’s ophthalmology program, according to a press release.

The FDA has approved a chemistry, manufacturing and controls prior-approval supplement for the Eylea injection prefilled syringe, Regeneron announced in a press release.